Inotiv, Inc. announces the opening of a new construction

WEST LAFAYETTE, Ind., November 10, 2021 (GLOBE NEWSWIRE) – November 10, 2021 – Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in non-clinical and analytical drug discovery and development services and research models and related products and services, today announced the opening of its newly opened scientific laboratories. built at its St. Louis facility with operations focused on supporting clients in the areas of drug metabolism and pharmacokinetics (DMPK), cell and molecular biology, pharmacology, toxicology and histopathology.

“New state-of-the-art DMPK and Cellular and Molecular Biology laboratories, archives and offices extend our capabilities to support clients from the early stages of drug discovery through clinical development,” said Scott Daniels, Senior Vice President and Head of Site Operations. In addition, the concurrent investments in science and technology to equip this new construction, including improved mass spectrometry, flow cytometry and gene profiling platforms, effectively extend our coverage of the therapeutic landscape to include new biotherapeutics, ranging from oligonucleotides and proteins to gene therapies.

The completed project also includes an expanded histology lab and archive space to accommodate the growth of Inotiv’s pathology business resulting from the recent increase in the pharmacological footprint of discovery, as well as increased demand for toxicology in development.

“These expanded capabilities to serve our customers come at an ideal time, particularly given the recent acquisition of Envigo and the expansion of our in vivo pharmacology operations,” said John Sagartz, chief strategy officer for Inotiv. “The increased demand for pharmacological specialties and transgenic models coincides with a need for extensive laboratory science and associated expertise. The opening of these newly built labs is perfectly synchronized with our extensive drug discovery and development services at Inotiv. “

About the company

Inotiv, Inc. is a leading contract research organization dedicated to providing non-clinical and analytical drug discovery and development services, research models, and related products and services. The Company’s products and services focus on the introduction of new drugs and medical devices throughout the discovery and preclinical development phases, while increasing efficiency, improving data and reducing the cost of implementation. the market for new drugs. Inotiv is committed to supporting discovery and development goals as well as helping researchers realize the full potential of their critical R&D projects, while working together to build a healthier and safer world. More information about Inotiv can be found here: https://www.inotivco.com/.

This press release may contain forward-looking statements subject to risks and uncertainties, including, but not limited to, risks and uncertainties relating to changes in the market and demand for our products and services, development, marketing and sale of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and commercial and financial impact of these, the impact of the COVID-19 pandemic on the economy, demand for our services and products and operations, including actions taken by government authorities to deal with the pandemic, which may precipitate or exacerbate others risks and / or uncertainties, expansion and related efforts, and various other market and operational risks, including those detailed in the documents filed by the Company with the United States Securities and Exchange Commission.

Comments are closed.